Abstract

Sodium glucose co-transporter-2 inhibitors have been shown to have multiple cardiovascular and renal benefits in patients with type 2 diabetes. In large randomised controlled trials they reduced major cardiovascular outcomes, hospitalisation for heart failure and adverse kidney outcomes, independently of their glucose-lowering effects. They are simple to prescribe and do not require dose titration. Compelling indications for this class of medications in patients with type 2 diabetes include those at high or very high risk of cardiovascular events and those with established atherosclerotic cardiovascular disease. They are also indicated for patients with heart failure and chronic kidney disease, regardless of diabetic status.

Details

Title
Cardiorenal effects of SGLT2 inhibitors: who might benefit?
Author
Klug, E 1 ; Rayner, B 2 ; Wasserfall, M 3 ; Kok, A 4 ; Mpe, M 5 ; Ruder, S 6 ; NA, Mohamed 7 ; Webb, D 8   VIAFID ORCID Logo 

1  Netcare Sunninghill and Sunward Park Hospitals, Division of Cardiology, Charlotte Maxeke Johannesburg Academic Hospital, South Africa; 
2  Division of Nephrology and Hypertension, Groote Schuur Hospital, South Africa; 
3  Mediclinic Panorama, South Africa; 
4  Netcare Alberton Hospital, South Africa; 
5  Mediclinic Heart Hospital, South Africa; 
6  Life Healthcare, South Africa; 
7  Division of Endocrinology, Chris Hani Baragwanath Academic Hospital, University of Witwatersrand, South Africa; 
8  Houghton House Addiction & Mental Health Treatment Centres, South Africa 
Pages
8-17
Publication year
2024
Publication date
Apr 2024
Publisher
Medpharm Publications
ISSN
16089677
e-ISSN
22201009
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1080/16089677.2023.2275898
ProQuest document ID
3037737884
Copyright
© 2023 The Author(s). Co-published by NISC Pty (Ltd) and Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons  Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.